Andreas Hochhaus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7480573/publications.pdf

Version: 2024-02-01

413 papers	59,786 citations	2322 98 h-index	1027 235 g-index
426 all docs	426 docs citations	426 times ranked	25990 citing authors

#	Article	IF	Citations
1	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1569-1583.	2.5	3
2	YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia, 2022, 36, 426-437.	7.2	18
3	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 2022, 139, 1080-1097.	1.4	16
4	Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2539-2548.	2.5	2
5	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	17.0	33
6	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia, 2022, 36, 1834-1842.	7.2	10
7	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022, 36, 1825-1833.	7.2	43
8	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
9	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
10	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia, 2022, 36, 1879-1886.	7.2	5
11	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021, 35, 440-453.	7.2	159
12	Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update. Hematologic Malignancies, 2021, , 105-117.	0.2	2
13	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia, 2021, 35, 1344-1355.	7.2	43
14	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3081-3089.	2.5	14
15	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	1.4	95
16	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041.	1.4	147
17	Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	1
18	Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 81-89.	2.8	45

#	Article	IF	Citations
19	EZH2 in Myeloid Malignancies. Cells, 2020, 9, 1639.	4.1	37
20	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 2020, 588, 157-163.	27.8	90
21	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	3.5	29
22	Expert opinionâ€"management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia, 2020, 34, 1495-1502.	7.2	63
23	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 2020, 34, 2074-2086.	7.2	50
24	Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia, 2020, 34, 2198-2205.	7.2	26
25	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia, 2020, 34, 2113-2124.	7.2	22
26	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137.	7.2	47
27	CML - Not only BCR-ABL1 matters. Best Practice and Research in Clinical Haematology, 2020, 33, 101194.	1.7	6
28	Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia. Cells, 2020, 9, 444.	4.1	6
29	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020, 34, 2138-2149.	7.2	55
30	Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. BMC Medical Informatics and Decision Making, 2020, 20, 28.	3.0	12
31	Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. Journal of Cellular and Molecular Medicine, 2020, 24, 2942-2955.	3.6	8
32	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia, 2020, 34, 2064-2073.	7.2	35
33	Treatment-free remission in FIP1L1-PDGFRAâ€"positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Advances, 2020, 4, 440-443.	5.2	27
34	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <scp>PCM1â€JAK2</scp>, <scp>BCRâ€JAK2</scp> and <scp>ETV6â€ABL1</scp> fusion genes. American Journal of Hematology, 2020, 95, 824-833.	4.1	46
35	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica, 2019, 104, 93-101.	3.5	62
36	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American Journal of Hematology, 2019, 94, 1236-1243.	4.1	17

#	Article	IF	Citations
37	5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2835-2843.	2.5	11
38	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	7.2	97
39	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1589-1599.	2.5	21
40	Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). Journal of Cancer Research and Clinical Oncology, 2019, 145, 1645-1650.	2.5	10
41	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	27.0	257
42	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 2019, 104, 955-962.	3.5	18
43	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 2018, 32, 1222-1228.	7.2	22
44	Therapy-free remission in chronic myeloid leukemia: possible mechanism. Expert Review of Hematology, 2018, 11, 269-272.	2.2	9
45	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	10.7	444
46	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell, 2018, 173, 470-484.e18.	28.9	89
47	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	1.4	392
48	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237.	1.6	356
49	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Research, 2018, 78, 6223-6234.	0.9	16
50	Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Advances, 2018, 2, 1572-1579.	5.2	24
51	Dasatinib. Recent Results in Cancer Research, 2018, 212, 29-68.	1.8	48
52	Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood, 2018, 132, 307-320.	1.4	66
53	Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia, 2018, 32, 2046-2049.	7.2	37
54	PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget, 2018, 9, 9442-9455.	1.8	11

#	Article	IF	Citations
55	Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Hematology, 2017, 22, 93-98.	1.5	10
56	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. Journal of Cancer Research and Clinical Oncology, 2017, 143, 843-850.	2.5	34
57	Reply to K.R. Hoffman. Journal of Clinical Oncology, 2017, 35, 567-568.	1.6	4
58	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 2017, 376, 917-927.	27.0	926
59	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1225-1233.	2.5	9
60	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2017, 35, 175-184.	1.6	36
61	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica, 2017, 102, 1361-1367.	3.5	28
62	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2059-2066.	2.5	6
63	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1585-1596.	2.5	29
64	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomeâ€positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	4.1	79
65	Isoform localization of Dectinâ€1 regulates the signaling quality of antiâ€fungal immunity. European Journal of Immunology, 2017, 47, 848-859.	2.9	31
66	Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. Haematologica, 2017, 102, e39-e42.	3.5	2
67	High BCRâ€“ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. Clinical Cancer Research, 2017, 23, 7189-7198.	7.0	34
68	Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2511-2519.	2.5	6
69	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of Hematology, 2017, 96, 1463-1470.	1.8	48
70	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology, 2017, 143, 337-345.	2.5	17
71	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	7.0	38
72	Chronische myeloproliferative Neoplasien (CMPN). , 2017, , 395-420.		0

#	Article	IF	Citations
73	Prognostic Impact of mRNA Expression Levels of HER1â€“4 (ERBB1â€“4) in Patients with Locally Advanced Rectal Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-9.	1.5	2
74	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0150632.	2.5	34
75	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clinical Cancer Research, 2016, 22, 4030-4038.	7.0	20
76	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	10.7	214
77	EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1641-1650.	2.5	31
78	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 2016, 127, 703-712.	1.4	87
79	Dasatinib in imatinibâ€resistant or â€intolerant chronicâ€phase, chronic myeloid leukemia patients: 7â€year followâ€up of study CA180â€034. American Journal of Hematology, 2016, 91, 869-874.	4.1	145
80	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer, 2016, 122, 1398-1407.	4.1	47
81	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Research, 2016, 48, 84-91.	0.8	130
82	Standardization of Molecular Monitoring for Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , 89-98.	0.2	0
83	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2603-2610.	2.5	7
84	Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. Annals of Hematology, 2016, 95, 1899-1901.	1.8	5
85	Response-Related Predictors of Survival in CML. Hematologic Malignancies, 2016, , 129-145.	0.2	0
86	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-NaÃ¯ve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology, 2016, 34, 2333-2340.	1.6	724
87	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2016, 142, 317-324.	2.5	19
88	Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature. Acta Haematologica, 2016, 135, 1-10.	1.4	23
89	Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1133-1136.	2.5	0
90	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	30.7	94

#	Article	IF	Citations
91	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 2016, 30, 1044-1054.	7.2	685
92	Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin. Annals of Hematology, 2016, 95, 355-357.	1.8	4
93	Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection, 2016, 44, 175-186.	4.7	16
94	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia, 2015, 29, 1832-1838.	7.2	58
95	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood, 2015, 126, 42-49.	1.4	171
96	Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Annals of Hematology, 2015, 94, 219-225.	1.8	42
97	Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Annals of Hematology, 2015, 94, 133-140.	1.8	26
98	Response-related predictors of survival in CML. Annals of Hematology, 2015, 94, 227-239.	1.8	25
99	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1661-1668.	2.5	10
100	Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2047-2060.	2.5	50
101	Lower gastrointestinal bleeding in a patient with Crohnâ€™s disease and plasma cell leukemia in remission. Annals of Hematology, 2015, 94, 2063-2065.	1.8	2
102	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	1.8	67
103	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 2015, 141, 887-899.	2.5	67
104	Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular spheroids. Journal of Magnetism and Magnetic Materials, 2015, 380, 27-33.	2.3	28
105	Chronic Myelogeneous Leukemia. , 2015, , 85-99.		1
106	Campylobacter jejuni ssp. jejuni bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy. JMM Case Reports, 2015, 2, .	1.3	0
107	Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World Journal of Gastroenterology, 2014, 20, 15820.	3.3	20
108	Reply to H. Kantarjian et al. Journal of Clinical Oncology, 2014, 32, 3078-3078.	1.6	3

#	Article	IF	Citations
109	Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica, 2014, 99, 7-18.	3.5	47
110	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica, 2014, 99, 1441-1447.	3.5	97
111	Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5â€azacytidine and literature review. European Journal of Haematology, 2014, 93, 247-259.	2.2	31
112	Paradoxical MAPKâ€activation in response to treatment with tyrosine kinase inhibitors in CML: Flow cytometry loses track. Cytometry Part B - Clinical Cytometry, 2014, 86, 229-235.	1.5	5
113	Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 829-837.	2.5	9
114	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	1.6	271
115	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80.	1.8	60
116	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1451-1462.	1.3	39
117	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2014, 123, 494-500.	1.4	364
118	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Annals of Hematology, 2014, 93, 81-88.	1.8	142
119	Older patients with chronic myeloid leukemia (â‰¥65Âyears) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of Hematology, 2014, 93, 1167-1176.	1.8	21
120	Different clones of acute leukemia after successful treatment of Hodgkinâ€™s disease. Annals of Hematology, 2014, 93, 2077-2079.	1.8	0
121	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1367-1381.	2.5	5
122	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). Journal of Cancer Research and Clinical Oncology, 2014, 140, 1391-1397.	2.5	5
123	Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1965-1969.	2.5	31
124	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 2014, 99, 1204-1211.	3.5	42
125	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 2014, 123, 1353-1360.	1.4	231
126	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood, 2014, 123, 2317-2324.	1.4	167

#	Article	IF	Citations
127	Optimizing tolerability of TKI therapy in CML. Blood, 2014, 123, 1284-1285.	1.4	7
128	Dasatinib. Recent Results in Cancer Research, 2014, 201, 27-65.	1.8	68
129	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	1.4	43
130	Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients. Blood, 2014, 124, 4546-4546.	1.4	15
131	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. Blood, 2014, 124, 4552-4552.	1.4	8
132	LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget, 2014, 5, 5257-5271.	1.8	19
133	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 2013, 13, 173.	2.6	16
134	Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Annals of Hematology, 2013, 92, 1071-1077.	1.8	14
135	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). Journal of Cancer Research and Clinical Oncology, 2013, 139, 1397-1404.	2.5	13
136	The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. Journal of Cancer Research and Clinical Oncology, 2013, 139, 605-615.	2.5	9
137	Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Annals of Hematology, 2013, 92, 1345-1350.	1.8	47
138	Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. Annals of Hematology, 2013, 92, 907-915.	1.8	1
139	Clonal T-LGL population mimicking leukemia in Feltyâ€™s syndromeâ€”part of a continuous spectrum of T-LGL proliferations?. Annals of Hematology, 2013, 92, 985-987.	1.8	10
140	Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany. Annals of Hematology, 2013, 92, 825-830.	1.8	7
141	The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1971-1984.	2.5	48
142	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1985-1993.	2.5	10
143	Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 584-591.	0.4	48
144	A Phase 2 Trial of Ponatinib in Philadelphia Chromosomeâ€“Positive Leukemias. New England Journal of Medicine, 2013, 369, 1783-1796.	27.0	944

#	Article	IF	Citations
145	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 2013, 27, 107-112.	7.2	212
146	Comprehensive mutational profiling in advanced systemic mastocytosis. Blood, 2013, 122, 2460-2466.	1.4	222
147	The E3 ubiquitin ligase TRAF2 can contribute to TNF-Î± resistance in FLT3-ITD-positive AML cells. Leukemia Research, 2013, 37, 1557-1564.	0.8	10
148	Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles. IEEE Transactions on Magnetics, 2013, 49, 383-388.	2.1	16
149	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	3.2	46
150	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 2013, 27, 907-913.	7.2	23
151	Genotyping of 25 Leukemia-Associated Genes in a Single Work Flow by Next-Generation Sequencing Technology with Low Amounts of Input Template DNA. Clinical Chemistry, 2013, 59, 1238-1250.	3.2	18
152	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	1.4	1,743
153	The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica, 2013, 98, 714-717.	3.5	18
154	Complete Remission After Treatment With Single-Agent Ofatumumab in a Patient With High-Risk Leukemic Mantle-Cell Lymphoma. Journal of Clinical Oncology, 2013, 31, e312-e315.	1.6	8
155	Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 1473.	7.4	1,447
156	Die hÃmophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik. Laboratoriums Medizin, 2013, 37, 217-225.	0.6	1
157	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2013, 121, 3703-3708.	1.4	91
158	Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood, 2013, 121, 378-384.	1.4	68
159	The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica, 2013, 98, 1510-1516.	3.5	61
160	Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications, 2013, 5, 85.	1.2	50
161	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2013, 122, 652-652.	1.4	6
162	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. Blood, 2013, 122, 653-653.	1.4	24

#	Article	IF	Citations
163	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
164	Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosomeâ€“Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. Journal of Clinical Oncology, 2012, 30, 4323-4329.	1.6	90
165	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012, 119, 1123-1129.	1.4	520
166	Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen LeukÃmie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leukemia: recommendations from a German expert panel. Laboratoriums Medizin, 2012, 36, .	0.6	0
167	Imatinib and Beyond â€“ Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. Onkologie, 2012, 35, 34-41.	0.8	3
168	Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood, 2012, 119, 530-539.	1.4	81
169	Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?. Blood, 2012, 119, 2965-2966.	1.4	7
170	Rac2-MRC-cIIIâ€“generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 2012, 119, 4253-4263.	1.4	147
171	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Annals of Hematology, 2012, 91, 1713-1720.	1.8	29
172	Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology, The, 2012, 13, 579-588.	10.7	428
173	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, 2012, 30, 3596-3603.	1.6	134
174	Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC Blood Disorders, 2012, 12, 9.	0.9	13
175	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 70, 345-350.	2.3	25
176	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012, 26, 2096-2102.	7.2	383
177	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood, 2012, 119, 5963-5971.	1.4	69
178	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 2012, 26, 2197-2203.	7.2	395
179	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 2012, 68, 723-733.	1.9	86
180	Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Seminars in Oncology, 2012, 39, 58-66.	2.2	52

#	Article	IF	Citations
181	Ponatinib may overcome resistance of <scp>FLT</scp>3â€<scp>ITD</scp> harbouring additional point mutations, notably the previously refractory <scp>F</scp>691I mutation. British Journal of Haematology, 2012, 157, 483-492.	2.5	46
182	Lericheâ€™s syndrome and LÃ¶ffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome. Annals of Hematology, 2012, 91, 139-141.	1.8	2
183	Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of Cancer Research and Clinical Oncology, 2012, 138, 203-212.	2.5	7
184	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood, 2012, 120, 163-163.	1.4	34
185	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	1.4	17
186	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. Blood, 2012, 120, 1675-1675.	1.4	18
187	Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose â€“ Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV. Blood, 2012, 120, 67-67.	1.4	5
188	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0 0 rgBT /Overlock 1	1.4	0
189	Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.. Journal of Clinical Oncology, 2012, 30, 6504-6504.	1.6	28
190	Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. Journal of Clinical Oncology, 2012, 30, 6506-6506.	1.6	15
191	BCR-ABL Mutations in Chronic Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 997-1008.	2.2	44
192	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 524-531.	1.6	84
193	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011, 118, 1208-1215.	1.4	486
194	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology, The, 2011, 12, 841-851.	10.7	444
195	KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1032-1038.	0.8	46
196	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 2011, 117, 1141-1145.	1.4	344
197	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood, 2011, 117, 2935-2943.	1.4	76
198	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood, 2011, 117, 5600-5606.	1.4	60

#	Article	IF	Citations
199	Response of ETV6-FLT3â€“positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011, 118, 2239-2242.	1.4	75
200	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood, 2011, 118, 5697-5700.	1.4	53
201	Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica, 2011, 96, 360-366.	3.5	44
202	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	3.5	15
203	Subclones with the t(9;22)/BCRâ€ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. British Journal of Haematology, 2011, 152, 713-720.	2.5	58
204	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell, 2011, 19, 740-753.	16.8	124
205	Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 733-738.	2.5	63
206	Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1293-1300.	2.5	15
207	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Annals of Hematology, 2011, 90, 365-366.	1.8	6
208	Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Annals of Hematology, 2011, 90, 473-475.	1.8	10
209	Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkinâ€™s lymphoma. Annals of Hematology, 2011, 90, 857-859.	1.8	1
210	Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment. Annals of Hematology, 2011, 90, 1353-1355.	1.8	11
211	Current Treatment Concepts of CML. Current Cancer Drug Targets, 2011, 11, 31-43.	1.6	17
212	BCRâ€“ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment. Clinical Cancer Research, 2011, 17, 6812-6821.	7.0	46
213	Cancer Patients and the Internet: A Survey of the â€˜Quality of Lifeâ€™ Working Groups of the Arbeitsgemeinschaft fÃ¼r Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft fÃ¼r GynÃ¤kologische Onkologie. Onkologie, 2011, 34, 435-440.	0.8	7
214	Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease. Hematology American Society of Hematology Education Program, 2011, 2011, 128-135.	2.5	47
215	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-Î± in Newly Diagnosed Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1634-1642.	1.6	307
216	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine, 2011, 208, 2163-2174.	8.5	154

#	Article	IF	Citations
217	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011, 118, 6760-6768.	1.4	254
218	Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia. Cell Cycle, 2011, 10, 250-260.	2.6	64
219	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. Blood, 2011, 118, 3770-3770.	1.4	5
220	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Blood, 2011, 118, 452-452.	1.4	11
221	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica, 2010, 95, 1473-1480.	3.5	67
222	Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Current Opinion in Hematology, 2010, 17, 91-96.	2.5	14
223	A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon Â. Haematologica, 2010, 95, 148-152.	3.5	29
224	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica, 2010, 95, 738-744.	3.5	72
225	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, 115, 1880-1885.	1.4	198
226	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010, 116, 3758-3765.	1.4	440
227	Dasatinib. Recent Results in Cancer Research, 2010, 184, 83-102.	1.8	48
228	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2260-2270.	27.0	1,411
229	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2251-2259.	27.0	1,497
230	Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1845-1851.	2.5	3
231	Detection of centrosome aberrations in diseaseâ€unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. European Journal of Haematology, 2010, 85, 139-148.	2.2	14
232	Atypical mRNA fusions in PMLâ€RARA positive, RARAâ€PML negative acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2010, 49, 471-479.	2.8	26
233	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer, 2010, 116, 1419-1430.	4.1	40
234	Phase 1 study of INNOâ€406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosomeâ€positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116, 2665-2672.	4.1	45

#	Article	IF	Citations
235	Dasatinib in imatinibâ€resistant or imatinibâ€intolerant chronic myeloid leukemia in blast phase after 2 years of followâ€up in a phase 3 study. Cancer, 2010, 116, 3852-3861.	4.1	115
236	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 2010, 42, 722-726.	21.4	1,034
237	Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1429-1435.	1.6	153
238	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 2010, 95, 232-240.	3.5	231
239	Detection of Drug-Resistant Clones in Chronic Myelogenous Leukemia Patients during Dasatinib and Nilotinib Treatment. Clinical Chemistry, 2010, 56, 469-473.	3.2	14
240	Reply to V. Pitini et al. Journal of Clinical Oncology, 2010, 28, e440-e440.	1.6	1
241	An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 4666-4674.	7.0	78
242	Short-Term Application of Magnetic Core-Shell Nanoparticlesâ€"Effect on Immune Cells. , 2010, , .		2
243	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	1.4	141
244	Annexin and Survivin in Locally Advanced Rectal Cancer: Indicators of Resistance to Preoperative Chemoradiotherapy?. Onkologie, 2010, 33, 439-444.	0.8	9
245	Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. Blood, 2010, 116, 2286-2286.	1.4	53
246	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. Blood, 2010, 116, 2291-2291.	1.4	12
247	Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial. Blood, 2010, 116, 2295-2295.	1.4	11
248	Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.. Blood, 2010, 116, 3421-3421.	1.4	13
249	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	1.6	181
250	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 551-558.	1.3	16
251	Presentation, Treatment, and Analysis of Prognostic Factors of Terminally ill Patients with Gastrointestinal Tumors. Onkologie, 2009, 32, 2-2.	0.8	21
252	Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114, 5271-5278.	1.4	109

#	Article	IF	Citations
253	Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. Journal of Clinical Oncology, 2009, 27, 4204-4210.	1.6	292
254	Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. Cancer Genetics and Cytogenetics, 2009, 189, 63-67.	1.0	11
255	Identification of a MYO18Aâ€PDGFRB fusion gene in an eosinophiliaâ€associated atypical myeloproliferative neoplasm with a t(5;17)(q33â€34;q11.2). Genes Chromosomes and Cancer, 2009, 48, 179-183.	2.8	35
256	Combined Adjuvant Radiochemotherapy With IMRT/XELOX Improves Outcome With Low Renal Toxicity in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1187-1195.	0.8	35
257	Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, 2009, 23, 1628-1633.	7.2	35
258	Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancerâ€"An Extended Phase I MARGIT and AIO Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 142-147.	0.8	21
259	A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias. Leukemia Research, 2009, 33, e168-e169.	0.8	0
260	Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1487-1493.	0.8	104
261	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	1.6	1,188
262	Cause and management of therapy resistance. Best Practice and Research in Clinical Haematology, 2009, 22, 367-379.	1.7	17
263	Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. Oncology, 2009, 77, 293-299.	1.9	82
264	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23, 1054-1061.	7.2	808
265	Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy. Seminars in Hematology, 2009, 46, S11-S15.	3.4	6
266	Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anti-Cancer Drugs, 2009, 20, 519-524.	1.4	29
267	Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin. Anti-Cancer Drugs, 2009, 20, 75-78.	1.4	9
268	A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica, 2009, 94, 1227-1235.	3.5	36
269	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood, 2009, 114, 4944-4953.	1.4	271
270	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Blood, 2009, 114, 1126-1126.	1.4	358

#	Article	IF	Citations
271	Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.. Blood, 2009, 114, 339-339.	1.4	16
272	Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutationâ€"Results of An Ongoing Multicenter Phase 2/3 Study.. Blood, 2009, 114, 644-644.	1.4	20
273	Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors â€" Results of A Multicenter Phase 2/3 Study.. Blood, 2009, 114, 861-861.	1.4	16
274	Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.. Blood, 2009, 114, 862-862.	1.4	4
275	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. Blood, 2009, 114, 4272-4272.	1.4	11
276	International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Research, 2008, 32, 505-506.	0.8	30
277	mRNA Expression of Platelet-Derived Growth Factor Receptor-Î² and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1544-1550.	0.8	16
278	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 2008, 22, 1200-1206.	7.2	341
279	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome â€" a phaseâ€‖ study. British Journal of Haematology, 2008, 143, 707-715.	2.5	128
280	Resistance to imatinib in chronic myelogenous leukemia: Mechanisms and clinical implications. Current Hematologic Malignancy Reports, 2008, 3, 72-79.	2.3	7
281	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 3204-3212.	1.6	458
282	Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica, 2008, 93, 186-192.	3.5	98
283	Suitability of the PAXgeneâ„¢ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia. Clinical Chemistry and Laboratory Medicine, 2008, 46, 318-22.	2.3	6
284	Prognostic Factors in Chronic Myeloid Leukemia (CML). Oncology Research and Treatment, 2008, 31, 576-578.	1.2	2
285	Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica, 2008, 93, 1145-1154.	3.5	38
286	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 2008, 93, 1389-1393.	3.5	48
287	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111, 1834-1839.	1.4	284
288	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-Î± treatment. Blood, 2008, 111, 1039-1043.	1.4	195

#	Article	IF	Citations
289	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008, 112, 3330-3338.	1.4	350
290	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica, 2008, 93, 765-769.	3.5	41
291	Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica, 2008, 93, 178-185.	3.5	18
292	Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. Blood, 2008, 112, 184-184.	1.4	8
293	Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2008, 112, 3216-3216.	1.4	12
294	Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035. Blood, 2008, 112, 3226-3226.	1.4	13
295	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia â€“ An Interim Analysis of the Randomized German CML Study IV. Blood, 2008, 112, 333-333.	1.4	10
296	Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Blood, 2008, 112, 334-334.	1.4	15
297	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. Blood, 2008, 112, 448-448.	1.4	3
298	Genomic instability in context of the chromosomal theory. Cellular Oncology, 2008, 30, 503-4.	1.9	3
299	Management of Bcrâ€“Abl-positive leukemias with dasatinib. Expert Review of Anticancer Therapy, 2007, 7, 1529-1536.	2.4	14
300	Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells. Haematologica, 2007, 92, 838-841.	3.5	19
301	Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. Archives of Dermatology, 2007, 143, 736-40.	1.4	71
302	Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opinion on Pharmacotherapy, 2007, 8, 3257-3264.	1.8	17
303	Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica, 2007, 92, 834-837.	3.5	39
304	An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica, 2007, 92, 970-973.	3.5	47
305	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood, 2007, 109, 2147-2155.	1.4	135
306	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007, 109, 4686-4692.	1.4	141

#	Article	IF	Citations
307	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood, 2007, 109, 4399-4405.	1.4	333
308	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007, 109, 2303-2309.	1.4	563
309	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRAâ€“positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	1.4	195
310	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 2007, 110, 727-734.	1.4	218
311	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, 110, 2309-2315.	1.4	349
312	Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood, 2007, 110, 1283-1290.	1.4	72
313	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, 110, 3540-3546.	1.4	688
314	Response: Drug treatment and allografting as first-line therapy in young patients with CML. Blood, 2007, 110, 4618-4619.	1.4	0
315	Chronic myeloid leukaemia. Lancet, The, 2007, 370, 342-350.	13.7	423
316	Resistance to Targeted Therapy in Chronic Myelogenous Leukemia. Seminars in Hematology, 2007, 44, 15-24.	3.4	111
317	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncology, The, 2007, 8, 658-660.	10.7	72
318	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, 109, 3207-3213.	1.4	400
319	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	1.4	352
320	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor Â gene. Haematologica, 2007, 92, 163-169.	3.5	84
321	Diagnosis and management of chronic myeloid leukemia. Cancer, 2007, 109, 1365-1375.	4.1	41
322	Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 2007, 109, 1543-1549.	4.1	57
323	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosomeâ€negative cells. Cancer, 2007, 110, 1509-1519.	4.1	121
324	Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer, 2007, 7, 345-356.	28.4	588

#	Article	IF	Citations
325	Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. British Journal of Haematology, 2007, 138, 369-373.	2.5	32
326	Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon Î±2a (PegasysÂ®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.. Blood, 2007, 110, 1027-1027.	1.4	2
327	Sustained Molecular Responses with Interferon Î±2a Maintenance Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase Chronic Myelogenous Leukemia.. Blood, 2007, 110, 28-28.	1.4	3
328	Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.. Blood, 2007, 110, 320-320.	1.4	12
329	Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).. Blood, 2007, 110, 734-734.	1.4	19
330	Chronische myeloproliferative Erkrankungen (CMPE). , 2007, , 377-400.		0
331	Stammzellerkrankungen. , 2007, , 309-326.		0
332	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	1.4	1,117
333	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	1.4	1,184
334	Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft fÃ¼r Internistische Onkologie (AIO). Oncology Research and Treatment, 2006, 29, 563-567.	1.2	14
335	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 2006, 107, 3339-3341.	1.4	113
336	Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine, 2006, 12, 1181-1184.	30.7	326
337	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 2006, 20, 1925-1930.	7.2	184
338	Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1384-1390.	0.8	96
339	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosomeâ€“Positive ALL. New England Journal of Medicine, 2006, 354, 2542-2551.	27.0	1,253
340	The results of imatinib therapy for patients with primary eosinophilic disorders. European Journal of Haematology, 2006, 76, 535-536.	2.2	22
341	Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes and Cancer, 2006, 45, 401-410.	2.8	41
342	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2â€PDGFRA fusion gene. Genes Chromosomes and Cancer, 2006, 45, 950-956.	2.8	72

#	Article	IF	Citations
343	Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7444-7449.	7.1	121
344	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine, 2006, 355, 2408-2417.	27.0	3,212
345	Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.. Blood, 2006, 108, 748-748.	1.4	9
346	The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 2006, 91, 452-9.	3.5	87
347	Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs, 2005, 16, 691-707.	1.4	294
348	Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drugs, 2005, 16, 39-45.	1.4	9
349	Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anti-Cancer Drugs, 2005, 16, 435-440.	1.4	20
350	Response and resistance in 300 patients with BCRâ€ABLâ€“positive leukemias treated with imatinib in a single center. Cancer, 2005, 103, 1659-1669.	4.1	207
351	Chronic myeloid leukemia: a model for oncology. Annals of Hematology, 2005, 84, 487-497.	1.8	49
352	Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta OncolÃ³gica, 2005, 44, 168-173.	1.8	12
353	Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. Journal of Clinical Oncology, 2005, 23, 7583-7593.	1.6	89
354	The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2. Cancer Research, 2005, 65, 2662-2667.	0.9	269
355	Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer. Journal of Clinical Oncology, 2005, 23, 1350-1357.	1.6	100
356	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.	1.4	798
357	Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-Î±.. Blood, 2005, 106, 1089-1089.	1.4	11
358	Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 â€˜START-Câ€™ Phase II Study.. Blood, 2005, 106, 41-41.	1.4	17
359	Stammzellerkrankungen. , 2005, , 275-290.		0
360	In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica, 2005, 90, 459-64.	3.5	51

#	Article	IF	Citations
361	Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era â€“ Evaluation of Response and Resistance. Acta Haematologica, 2004, 112, 85-92.	1.4	6
362	Minimal Residual Disease in Hematological Malignancies. Acta Haematologica, 2004, 112, 5-7.	1.4	3
363	Standardization of Preanalytical Factors for Minimal Residual Disease Analysis in Chronic Myelogenous Leukemia. Acta Haematologica, 2004, 112, 30-33.	1.4	27
364	Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Annals of Hematology, 2004, 83, 477-480.	1.8	25
365	Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemotherapy and Pharmacology, 2004, 53, 276-278.	2.3	29
366	Clinical resistance to imatinib: mechanisms and implications. Hematology/Oncology Clinics of North America, 2004, 18, 641-656.	2.2	80
367	Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 657-670.	2.2	18
368	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 2004, 103, 3480-3489.	1.4	96
369	Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients.. Blood, 2004, 104, 1013-1013.	1.4	6
370	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. Blood, 2004, 104, 23-23.	1.4	61
371	Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. Blood, 2004, 104, 2428-2428.	1.4	4
372	PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.. Blood, 2004, 104, 4662-4662.	1.4	0
373	Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 142, 162-164.	1.0	2
374	Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2003, 36, 175-188.	2.8	58
375	ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia Research, 2003, 27, 1163-1166.	0.8	15
376	Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia. Annals of the New York Academy of Sciences, 2003, 996, 26-38.	3.8	28
377	Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 349, 1423-1432.	27.0	1,118
378	Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology, 2003, 40, 69-79.	3.4	57

#	Article	IF	Citations
379	Comments on the Hammersmith policy. Seminars in Hematology, 2003, 40, 109-110.	3.4	0
380	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	27.0	3,227
381	Interferon-Î±, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood, 2003, 101, 259-264.	1.4	131
382	Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood, 2003, 101, 375-375.	1.4	27
383	Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology, 2003, 40, 69-79.	3.4	50
384	Erkrankungen des Blutes. , 2003, , 281-408.		0
385	Comments on the Hammersmith policy. Seminars in Hematology, 2003, 40, 109-110.	3.4	0
386	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	2.9	139
387	Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancerâ€“a phase II study. Anti-Cancer Drugs, 2002, 13, 999-1004.	1.4	11
388	Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood, 2002, 99, 1766-1775.	1.4	66
389	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99, 1928-1937.	1.4	943
390	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.	1.4	1,096
391	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 2002, 100, 1965-1971.	1.4	534
392	Minimal residual disease in chronic myeloid leukaemia patients. Best Practice and Research in Clinical Haematology, 2002, 15, 159-178.	1.7	19
393	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine, 2002, 346, 645-652.	27.0	1,899
394	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 2001, 98, 2879-2880.	1.4	38
395	Expression of interferon-Î± (IFN-Î±) receptor 2c at diagnosis is associated with cytogenetic response in IFN-Î±â€“treated chronic myeloid leukemia. Blood, 2001, 97, 3568-3573.	1.4	21
396	Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-Î±. Blood, 2001, 97, 3648-3650.	1.4	78

#	Article	IF	Citations
397	Chronic myeloid leukemia and interferon-Î±: a study of complete cytogenetic responders. Blood, 2001, 98, 3074-3081.	1.4	309
398	Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A. Blood, 2001, 98, 3874-3875.	1.4	17
399	Real-Time Quantitative Y Chromosome-Specific PCR (QYCS-PCR) for Monitoring Hematopoietic Chimerism after Sex-Mismatched Allogeneic Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 419-425.	1.8	79
400	AraC-based pharmacotherapy of chronic myeloid leukaemia. Expert Opinion on Pharmacotherapy, 2001, 2, 1129-1135.	1.8	5
401	Molecular heterogeneity in complete cytogenetic responders after interferon-Î± therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood, 2000, 95, 62-66.	1.4	181
402	Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia: Correlation With Response to Interferon Alfa Therapy. Journal of Clinical Oncology, 2000, 18, 3331-3338.	1.6	45
403	Molecular heterogeneity in complete cytogenetic responders after interferon-Î± therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood, 2000, 95, 62-66.	1.4	3
404	Interferon-îœ€ Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. Blood, 1999, 94, 3668-3677.	1.4	91
405	Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease. Blood, 1999, 94, 1484-1486.	1.4	21
406	Chronic myelogenous leukemia: molecular and cellular aspects. Journal of Cancer Research and Clinical Oncology, 1998, 124, 643-660.	2.5	51
407	Should a platelet limit of 600 Ã— 10⁹/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal of Haematology, 1998, 100, 15-23.	2.5	119
408	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-Î±. British Journal of Haematology, 1998, 102, 1271-1278.	2.5	18
409	Molecular response of CML patients treated with interferonâ€Î± monitored by quantitative Southern blot analysis. British Journal of Haematology, 1997, 97, 86-93.	2.5	34
410	Lack of correlation between ABLâ€BCR expression and response to interferonâ€Î± in chronic myeloid leukaemia. British Journal of Haematology, 1996, 92, 684-686.	2.5	51
411	Chronische myeloische LeukÃmie: Absetzen der Therapie zurzeit nur experimentell. , 0, , .		0
412	Perspektivenwechsel: Ein Wirkstoff fÃ¼r mehrere Krebserkrankungen. , 0, , .		0
413	Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. Leukemia, 0, , .	7.2	5